JSPR, US4718712023

Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 million

Published on 10/16/2026 at 00:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jasper enrolled 18 patients in a Phase 2 kidney study on October 15, 2026. Jasper Therapeutics stock has a USD 17.7 million market value.

Pipeline milestones and valuation

Jasper completed enrollment of 18 IgA nephropathy patients on October 15, 2026.
William Blair resumed coverage with an Outperform rating and a USD 20.00 target on October 14, 2026.
Jasper's market capitalization was USD 17.7 million as of October 15, 2026.

JSPR, US4718712023, Illustration mit AI erstellt.

Jasper Therapeutics, Inc. (ISIN US4718712023) completed enrollment of 18 patients in the first cohort of its Phase 2 IgA nephropathy study on October 15, 2026. GlobeNewswire reported that the company expects initial interim data by year-end 2026 and plans first dosing in a focal segmental glomerulosclerosis cohort in the first quarter of 2027.

Three financing milestones shape the story

Jasper's July 20, 2026 private placement generated USD 132.0 million in gross proceeds, according to StockTitan. The filing also described up to 284,013,011 common shares registered for resale, a potential supply overhang for a company with a clinical-stage pipeline.

At a September 30, 2026 special meeting, 21,747,865 voting shares represented 65.36 percent of the outstanding common stock, according to StockTitan. Stockholders authorized a possible reverse split between 1-for-15 and 1-for-35 by December 31, 2026.

What does the 18-patient study add?

The cohort divides six patients each among Q2W, Q4W and Q8W maintenance schedules after induction. That design gives Jasper three dosing schedules to assess for safety, tolerability and initial efficacy before broader development.

Three dated milestones guide the next steps

The July 20, 2026 financing came first, followed by the September 30, 2026 meeting and the October 15, 2026 IgA nephropathy enrollment announcement. The sequence links capital access, share-structure decisions and a clinical development milestone within three months.

Initial interim IgA nephropathy data are expected by year-end 2026, while first dosing in the focal segmental glomerulosclerosis cohort is anticipated in the first quarter of 2027, according to GlobeNewswire.

Analyst interest meets financing risk

Investing.com reported on October 14, 2026 that William Blair resumed coverage with an Outperform rating and a USD 20.00 price target. The contrast is sharp: the latest available Nasdaq quote was USD 0.53 on October 15, 2026 at 4:00 p.m. ET, while the market capitalization was USD 17.7 million.

Nasdaq valuation remains speculative

Jasper's clinical timetable now offers an evidence point for investors to monitor, but the resale registration and approved reverse-split range keep capital structure risk central to the valuation.

Market context: Market report Nasdaq Composite.

More news and analyses on Jasper Therapeutics stock